about
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma.Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis.HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma.PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo modelBortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 studyMaintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myelomaMinimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
P50
Q36962747-6F1881B8-D78F-4418-8B9A-204554F06112Q38305518-D96C66BE-A832-4CB3-9250-DA50B85DAAA4Q38658649-A164717A-6FBB-4706-9FD3-DC511033442BQ38778519-18B9C39B-5AF3-47D0-9187-2933D69B82B3Q38953187-AC909470-BA04-4D92-AA37-E3A449D8DAB8Q39004271-44425393-7776-41C5-840D-236171EFA71DQ41666443-893E55B4-8445-4C6B-8517-7FA979DCA6D2Q48139344-F0FBE25D-8044-414D-8449-D307991B316CQ51812800-083FF84D-94AE-4C8C-8FC1-4503D1D663A2Q56364006-D81BB8B3-954B-4EB6-A2FE-556B86BD74CFQ56971945-2ABA9860-F4B6-4521-86FF-40FEDE5CE833Q89900891-4EB62A7B-80D7-4849-8146-5DCA78F68CF7Q93088915-52BFDC9F-AF9C-48BC-B734-6EB93B332DE1
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Marina Martello
@en
Marina Martello
@nl
type
label
Marina Martello
@en
Marina Martello
@nl
prefLabel
Marina Martello
@en
Marina Martello
@nl
P31
P496
0000-0001-8196-8707